Member Info for BuenaVista

When you unearthed Toukmoron as Derek, do you remember the initials of the person?
And how sure are you that you weren't sold a dummy / fed a red herring / sent on a wildgoose chase?

How far from development, by which I suppose you mean regulatory approval, do you think it is Scottytom? What needs to happen to get it on the market?

Massive dumps?
355,287 Sell* was fat fingers
immediately reversed and 35,287 trade went through.

Actually replied to RonnieH

TheTwat has predicted 120p, then 130p then 160p (that post now gone) and is bashing hard today so I guess he's being paid to drive it down to 160p, his masters being surprised by the strong support on the way down having given up on getting it to 120/130. Who's wanting to get in low or is still short?

.

So HC have been selling some 1,657,000 of their 3,068,421 repayment allocation at £1.72 per share in order to self-fund the acquisition of 2,400,000 more shares?

HC received 3,068,421 on 24 January and will receive 2,400,000 on 16 February making 5,468,421 in total, which is less than 3% of Avacta shares in issue as of Thursday, so no TR1 required you moron.

Let me put it another way.

They haven't received enough to generate a TR1 you moron

They haven't received enough to generate a TR1 you moron

So in that case they wouldn't have done due diligence? £55m on favourable terms seems a big bet if based solely on information in the public domain.

Bloody autocorrect!

Those 3 large prints at the end of Friday are about £62.4k short of £2.85m FWIW. That shortfall could be elsewhere in the listing of traders of course. If HC, then they wouldn't have sold all their holding. This could be a self-funding way to add to their holding before Avacta starts repayments in cash.

But are HC allowed to trade whilst they are privy to market sensitive information, assuming DD? According to SB, no, and that makes sense as it would clearly be insider trading.

This instance yeboha you're the clown.

This wasn't a quarterly repayment. It was a decision by the loaner to convert some of the loan to shares at the conversion price, £1.1875.

At the quarterly repayment, Avacta has to cover to make the repayment in cash or shares. In future, even at the next repayment on 18 April, Avacta may be cash-rich enough to make the repayment in cash and the loaner would be locked out of receiving and further shares from the loan.

I regard that as extremely positive - licensing deal incoming!

I'll now go and have a laugh at what the basher clowns have been writing!

Rubbish! The key opinion leaders in oncology will be there to detail timescales to market and when the next products will be coming along plus any licensing deals in the bag ... according to Toukmoron.

Try a bit of rape and pillage instead over the next couple of weeks then.

Toukmoron, you're a useless deramper. Just give it a rest and sit back and enjoy the ride everyone else is having ...which reminds me: that Kenny is one lucky guy ;0)

From my reading around the topic, FAPa seems to be involved in tiissue growth and regrowth/repair/scarring and is described as being upregulated compared to healthy tissues and sometimes explicitly healthy ADULT tissues.

e.g. https://www.google.com/search?q=fibroblast+fap+healthy+adult+tissues

Can someone with knowledge of the science shine a light on the age/stage of growth when children stop significant upregulation of FAPa? The obvious assumption is when growth stops around 17 or 18 but that's only an assumption - if growth starts to slow, so may FAPa upregulation (i.e. there's no sudden halt to the upregulation).

The mounted panto act is correct.

The conversion factor is 54/80.

This is because, going back to August 2021, Alan said the initial dose of AVA6000 of 80mg/m² was equivalent to 90% of the standard doxorubicin dose, which we took to be 60mg/m². This also matches up by calculating the molecular weights of the two.

So... 12 x 54 / 80 = 8.1 mg/m² of cequivalent
So... 12 mg AVA6000 : 2 mg doxorubicin is 8.1 : 2
Or 4.05 times the doxorubicin dosing